Yan Leyfman: Injectable Semaglutide Shows Significant Reductions in Weight and Pain for Osteoarthritis Patients
Yan Leyfman, Co-founder and Executive Director of MedNews Week shared a post on LinkedIn, highlighting a study by Henning Bliddal et al. adding his own thoughts:
“Study in 407 patients with mean age was 56, mean BMI 40.3, and mean WOMAC pain score 70.9 who had obesity & knee osteoarthritis with moderate-to-severe pain, treatment with once-weekly injectable semaglutide resulted in significantly greater reductions in body weight and pain related to knee osteoarthritis.”
Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis
Authors: Henning Bliddal, M.D., Harold Bays, M.D., Sébastien Czernichow, M.D., Ph.D., Joanna Uddén Hemmingsson, M.D., Ph.D., Jøran Hjelmesæth, M.D., Ph.D., Thomas Hoffmann Morville, M.D., Ph.D., Anna Koroleva, M.D., Jesper Skov Neergaard, Ph.D., Patricia Vélez Sánchez, M.D., Sean Wharton, M.D., Alicja Wizert, Ph.D., and Lars E. Kristensen, M.D., Ph.D., for the STEP 9 Study Group
Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the medical correspondent at OncLive. He is also the Executive Committee Member at Music Beats Cancer. He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023